Ying Luo - Oct 30, 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Ying Luo
Stock symbol
GYRE
Transactions as of
Oct 30, 2023
Transactions value $
$0
Form type
4
Date filed
11/22/2023, 07:55 PM
Previous filing
Jan 5, 2023
Next filing
Nov 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GYRE Common Stock Other +2.84M 2.84M Oct 30, 2023 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Award $0 +3.35M $0.00 3.35M Nov 20, 2023 Common Stock 3.35M $0.75 Direct F3, F4
transaction GYRE Stock Option (Right to Buy) Award $0 +2.26M $0.00 2.26M Nov 20, 2023 Common Stock 2.26M $0.75 By Spouse F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock of the Issuer received by the spouse of the Reporting Person in exchange for the shares of Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability, held by the spouse of the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability,
F2 [cont'd from FN 1] GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent").
F3 Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
F4 These options are vested in full.